Abstract
The critical community size (CCS) is the minimum closed population size in which a pathogen can persist indefinitely. Below this threshold, stochastic extinction eventually causes pathogen extinction. Here we use a simulation model to explore behaviour-mediated persistence: a novel mechanism by which the population response to the pathogen determines the CCS. We model severe coronavirus 2 (SARS-CoV-2) transmission and non-pharmaceutical interventions (NPIs) in a population where both individuals and government authorities restrict transmission more strongly when SARS-CoV-2 case numbers are higher. This results in a coupled human-environment feedback between disease dynamics and population behaviour. In a parameter regime corresponding to a moderate population response, this feedback allows SARS-CoV-2 to avoid extinction in the trough of pandemic waves. The result is a very low CCS that allows long term pathogen persistence. Hence, an incomplete pandemic response represents a “sour spot” that not only ensures relatively high case incidence and unnecessarily long lockdown, but also promotes long-term persistence of the pathogen by reducing the CCS. Given the worldwide prevalence of small, isolated populations in which a pathogen with low CCS can persist, these results emphasize the need for a global approach to coronavirus disease 2019 (COVID-19) vaccination.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was funded by grants from the Ontario Ministry of Colleges and Universities and the Natural Sciences and Engineering Research Council of Canada (NSERC) Alliance program (to M.A. and C.T.B.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
1
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos